POST TRANSLATIONAL MEDICINES, INC.

Post Translational Medicines, Inc. is a US-based biotechnology firm specializing in innovative drug discovery solutions focused on the Dark Proteome, utilizing advanced technology to unlock new therapeutic targets. Post Translational Medicines, Inc. operates in the biotechnology sector, specifically targeting drug discovery solutions.

The company was founded independently by a team of experts in the field. Its headquarters is located in the United States. The company has recently raised USD 200,000 in pre-seed funding from investor Antler on June 27, 2025, marking a significant step in its funding journey, with a total amount raised of USD 200,000. Post Translational Medicines specializes in drug discovery solutions focused on the Dark Proteome—a largely uncharted area in biology that encompasses over six million proteoforms.

Their core product, the Surveyor™ Platform, is designed to systematically decode and target previously undruggable therapeutic targets, thereby offering novel pathways for restorative medicine and disease reversal. The platform leverages advanced structural biology and AI/machine learning integration to enhance the drug development process, catering primarily to biopharmaceutical companies and research institutions engaged in innovative drug discovery. The geographical markets for these products extend globally, targeting regions with robust pharmaceutical sectors, such as North America, Europe, and select markets in Asia, where there is a significant demand for therapeutic advancements. Post Translational Medicines generates revenue primarily through strategic partnerships and collaborations with biopharmaceutical firms and research institutions that utilize their Surveyor™ Platform and technology for drug development.

The transaction structure typically involves B2B agreements where clients access the platform through subscription models or project-based engagements. These partnerships may include tailored pricing plans based on the scope and duration of the services provided, particularly for flagship offerings that enhance in-cell drug discovery capabilities. The firm’s revenue model accommodates varying client needs, fostering long-term relationships with clients exploring the therapeutic potential of the Dark Proteome. Post Translational Medicines is positioned for future growth through the planned expansion of its Surveyor™ Platform to incorporate new features aimed at decoding additional therapeutic targets in the Dark Proteome.

The company is exploring entry into new markets in Europe and Asia by late 2025. The recent funding of USD 200,000 will be utilized to support product development and market expansion initiatives.